•
Dec 31, 2021
Avadel Q4 2021 Earnings Report
Announced fourth quarter and full year 2021 financial results and provided a corporate update.
Key Takeaways
Avadel Pharmaceuticals reported a net loss of $22.3 million for the fourth quarter of 2021. The company is focused on the FDA review for FT218 and preparing for its potential commercial launch.
FDA review of NDA for FT218 is ongoing, with commercial and launch preparations on track.
Expanded data portfolio supporting FT218's impact on narcolepsy with presentations at World Sleep 2022.
Appointed Dr. Douglas Williamson as Chief Medical Officer and Brandi Robinson as Senior Vice President, Corporate Affairs.
Extended the maturity on $117.4 million of convertible notes to October 2, 2023.
Avadel
Avadel
Forward Guidance
Avadel Pharmaceuticals is focused on completing the FDA review for FT218 and preparing for its potential commercial launch.